NZ 600112 Disclosed is the use of an isolated monoclonal antibody that specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor in the manufacture of a medicament for inhibiting undesired angiogenesis in a subject in need thereof. The disclosed antibody comprises a heavy chain (HC) variable domain and a light chain (LC) variable domain, wherein said heavy chain comprises 3 CDRs and said light chain comprises 3 CDRs, wherein the sequences of said CDRs of said antibody are as defined in the complete specification.
